The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Gilead Sciences Inc

Nasdaq: GILD
Last

(U.S.) $89.44

Today's change+2.08 +2.38%
Updated February 12 4:00 PM EST. Delayed by at least 15 minutes.
 

Gilead Sciences Inc

Nasdaq: GILD
Last

(U.S.) $89.44

Today's change+2.08 +2.38%
Updated February 12 4:00 PM EST. Delayed by at least 15 minutes.

Gilead Sciences Inc crosses above 20-day moving average

Gilead Sciences Inc closed up sharply Friday, rallying (U.S.)$2.08 or 2.38% to (U.S.)$89.44 and crossing above its 20-day moving average. Over the last five days, shares have gained 5.05%, but are down 11.61% for the last year to date. Shares have performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $88.66
  • Previous close(U.S.) $87.36
  • High(U.S.) $89.88
  • Low(U.S.) $86.68
  • Bid / Ask-- / --
  • YTD % change-11.61%
  • Volume11,311,721
  • Average volume (10-day)17,987,168
  • Average volume (1-month)14,143,288
  • Average volume (3-month)11,040,431
  • 52-week range(U.S.) $81.89 to (U.S.) $123.37
  • Beta1.00
  • Trailing P/E7.50×
  • P/E 1 year forward7.35×
  • Forward PEG5.19×
  • Indicated annual dividend(U.S.) $1.72
  • Dividend yield1.92%
  • Trailing EPS(U.S.) $11.92
Updated February 12 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+55.47%

Based on its net profit margin of 55.47%, Gilead Sciences Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX2.43%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue8,5068,2958,2447,594
Total other revenue--------
Total revenue8,5068,2958,2447,594
Gross profit7,4447,2317,2466,711
Total cost of revenue1,0621,064998883
Total operating expense2,8852,7102,6282,223
Selling / general / administrative1,066903812643
Research & development824743818694
Depreciation / amortization0------
Interest expense (income), net operating--------
Unusual expense (income)-67----3
Other operating expenses, total--------
Operating income5,6215,5855,6165,371
Interest income (expense), net non-operating-230-165-140-153
Gain (loss) on sale of assets--------
Other--------
Income before tax5,4375,4725,5115,239
Income after tax4,6854,5924,4974,332
Income tax, total7528801,014907
Net income4,6834,6004,4924,333
Total adjustments to net income--------
Net income before extra. items4,6834,6004,4924,333
Minority interest-28-51
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items4,6834,6004,4924,333
Inc. avail. to common incl. extra. items4,6834,6004,4924,333
Diluted net income4,6834,6004,4924,333
Dilution adjustment--------
Diluted weighted average shares1,4721,5031,5401,569
Diluted EPS excluding extraordinary itemsvalue per share3.183.062.922.76
Dividends per sharevalue per share0.430.430.430.00
Diluted normalized EPSvalue per share3.143.062.922.76